Business Description
Abbott Laboratories
NAICS : 339112
SIC : 3841
ISIN : US0028241000
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.52 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.38 | |||||
Debt-to-EBITDA | 1.42 | |||||
Interest Coverage | 11.5 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 5.22 | |||||
Beneish M-Score | -2.66 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.8 | |||||
3-Year EBITDA Growth Rate | 6.8 | |||||
3-Year EPS without NRI Growth Rate | 6.7 | |||||
3-Year FCF Growth Rate | -3.4 | |||||
3-Year Book Growth Rate | 6.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 8.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.48 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 43.38 | |||||
9-Day RSI | 45.45 | |||||
14-Day RSI | 49.59 | |||||
3-1 Month Momentum % | 4.45 | |||||
6-1 Month Momentum % | 11.28 | |||||
12-1 Month Momentum % | 11.56 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.6 | |||||
Quick Ratio | 1.14 | |||||
Cash Ratio | 0.52 | |||||
Days Inventory | 134.18 | |||||
Days Sales Outstanding | 59.46 | |||||
Days Payable | 82.06 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.86 | |||||
Dividend Payout Ratio | 0.48 | |||||
3-Year Dividend Growth Rate | 12.3 | |||||
Forward Dividend Yield % | 1.9 | |||||
5-Year Yield-on-Cost % | 3.47 | |||||
3-Year Average Share Buyback Ratio | 0.7 | |||||
Shareholder Yield % | 3.43 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 55.55 | |||||
Operating Margin % | 16.24 | |||||
Net Margin % | 13.99 | |||||
FCF Margin % | 15.7 | |||||
ROE % | 14.86 | |||||
ROA % | 7.9 | |||||
ROIC % | 10.65 | |||||
3-Year ROIIC % | -137.66 | |||||
ROC (Joel Greenblatt) % | 65.41 | |||||
ROCE % | 12.45 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 34.69 | |||||
Forward PE Ratio | 22.57 | |||||
PE Ratio without NRI | 25.25 | |||||
Shiller PE Ratio | 40.79 | |||||
Price-to-Owner-Earnings | 40.18 | |||||
PEG Ratio | 2.2 | |||||
PS Ratio | 4.84 | |||||
PB Ratio | 4.97 | |||||
Price-to-Tangible-Book | 22.5 | |||||
Price-to-Free-Cash-Flow | 30.76 | |||||
Price-to-Operating-Cash-Flow | 22.86 | |||||
EV-to-EBIT | 27.88 | |||||
EV-to-Forward-EBIT | 22.14 | |||||
EV-to-EBITDA | 19.38 | |||||
EV-to-Forward-EBITDA | 17.49 | |||||
EV-to-Revenue | 4.98 | |||||
EV-to-Forward-Revenue | 4.61 | |||||
EV-to-FCF | 31.63 | |||||
Price-to-GF-Value | 1.05 | |||||
Price-to-Projected-FCF | 1.9 | |||||
Price-to-DCF (Earnings Based) | 1.43 | |||||
Price-to-DCF (FCF Based) | 1.68 | |||||
Price-to-Median-PS-Value | 1.12 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.13 | |||||
Price-to-Graham-Number | 5.03 | |||||
Earnings Yield (Greenblatt) % | 3.59 | |||||
FCF Yield % | 3.28 | |||||
Forward Rate of Return (Yacktman) % | 11.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Abbott Laboratories Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 37,780.245 | ||
EPS (TTM) (€) | 3.012 | ||
Beta | 0.26 | ||
3-Year Sharpe Ratio | -0.07 | ||
3-Year Sortino Ratio | -0.1 | ||
Volatility % | 15.91 | ||
14-Day RSI | 49.59 | ||
14-Day ATR (€) | 1.204301 | ||
20-Day SMA (€) | 110.887 | ||
12-1 Month Momentum % | 11.56 | ||
52-Week Range (€) | 90.68 - 113.86 | ||
Shares Outstanding (Mil) | 1,734.46 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Abbott Laboratories Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Abbott Laboratories Stock Events
Event | Date | Price (€) | ||
---|---|---|---|---|
No Event Data |
Abbott Laboratories Frequently Asked Questions
What is Abbott Laboratories(WBO:ABT)'s stock price today?
When is next earnings date of Abbott Laboratories(WBO:ABT)?
Does Abbott Laboratories(WBO:ABT) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |